Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Andros Pharmaceuticals Co's Inventory Turnover for the
six
months ended in Dec. 2025 was 3.04.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Andros Pharmaceuticals Co's Inventory-to-Revenue for the
six
months ended in Dec. 2025 was 0.22.
Andros Pharmaceuticals Co (ROCO:6917) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Andros Pharmaceuticals Co's Inventory Turnover for the
six
months ended in Dec. 2025 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Andros Pharmaceuticals Co's Inventory to Revenue for the
six
months ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Andros Pharmaceuticals Co Days Inventory Related Terms
Andros Pharmaceuticals Co Days Inventory Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6917 vs VRTX, REGN, ALNY: Days Inventory Comparison
For the Biotechnology subindustry, Andros Pharmaceuticals Co's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Andros Pharmaceuticals Co Days Inventory vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Andros Pharmaceuticals Co's Days Inventory distribution charts can be found below:
* The bar in red indicates where Andros Pharmaceuticals Co's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Andros Pharmaceuticals Co (ROCO:6917) has a Days Inventory of 60.06 as of Dec. 2025. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Andros Pharmaceuticals Co and its competitors. This is 85% below median its historical median of 412.92. Over the past decade, Andros Pharmaceuticals Co's Days Inventory has ranged from 74.60 to 1,910.10. According to the industry distribution chart, Andros Pharmaceuticals Co ranks #195 out of 638 companies in the Biotechnology industry, placing it in the top 30.6%.
Is Andros Pharmaceuticals Co's Days Inventory too high?
Andros Pharmaceuticals Co's current Days Inventory of 60.06 is 85% below median its 10-year median of 412.92. Over the past 10 years, this metric has ranged from a low of 74.60 to a high of 1,910.10. The Biotechnology industry median Days Inventory is 183.20. Andros Pharmaceuticals Co's value of 60.06 is 67.2% below this industry median. Based on the distribution chart, Andros Pharmaceuticals Co ranks #195 out of 638 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Andros Pharmaceuticals Co has a GF Score™ of 42/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Andros Pharmaceuticals Co's Days Inventory compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Andros Pharmaceuticals Co ranks #195 out of 638 companies for Days Inventory. This puts Andros Pharmaceuticals Co in the upper half of its industry. The industry median Days Inventory is 183.20. Andros Pharmaceuticals Co's value of 60.06 is 67.2% below this benchmark. Historically, Andros Pharmaceuticals Co's own Days Inventory has ranged from 74.60 to 1,910.10 over the past decade. While the company's 10-year median is 412.92 vs. the industry median of 183.20, Andros Pharmaceuticals Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Biotechnology company?
The median Days Inventory among Biotechnology companies is 183.20, based on 638 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Andros Pharmaceuticals Co's current Days Inventory of 60.06 is 67.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Andros Pharmaceuticals Co and its competitors. For the Biotechnology industry, the median Days Inventory is 183.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Andros Pharmaceuticals Co's current Days Inventory is 60.06, which is 85% below median its own 10-year median of 412.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Andros Pharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Andros Pharmaceuticals Co (ROCO:6917) is currently considered Possible Value Trap. The stock's GF Value™ is NT$165.15, compared to a current price of NT$34.50 — trading 79.1% below its estimated fair value. The current Days Inventory is 60.06, which is 85% below median its 10-year median of 412.92 and 67.2% below the Biotechnology industry median of 183.20. Andros Pharmaceuticals Co's overall GF Score™ is 42/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Andros Pharmaceuticals Co (ROCO:6917), the current Days Inventory is 60.06 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Andros Pharmaceuticals Co (ROCO:6917) Overvalued in 2026?
Based on GuruFocus' analysis, Andros Pharmaceuticals Co stock appears to be undervalued.
The current stock price of NT$34.50 is trading 79.1% below its estimated GF Value™ of NT$165.15.
GuruFocus considers Andros Pharmaceuticals Co to be Possible Value Trap.
Key valuation signals for ROCO:6917:
Days Inventory: 60.06 (85% below median its 10-year median of 412.92)
GF Value™: NT$165.15 vs. price of NT$34.50 (79.1% below fair value)
Industry Position: 67.2% below the Biotechnology median (#195 of 638)
No single metric tells the full story. See the ROCO:6917 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Andros Pharmaceuticals Co Ltd is a biopharmaceutical company engaged in developing novel drug delivery platform technologies. The firm focuses on the development of topical new dosage forms and non-viral gene delivery systems, with the current pipeline indicated for pain management, DNA repair, and gene therapy. Its product line comprises New Dosage Forms (Topical), Super Generics (Topical), High-End Cosmetic Ingredients (Topical), and Gene Delivery Systems (Injectable).
42GF Score
Get the complete analysis for ROCO:6917
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6917 has been successfully added to your 
